![](https://blogger.googleusercontent.com/img/proxy/AVvXsEiOzt7a-gcOOpO1u2f6BtOif3qXzCX0gCD0egTtCA1fazw3ozfq4KFHn1ONDaM5QXmy2x4k-g68v32dqU8L3OvIkWNmvQtNv3UTZoGSNTGomDlx1WNaxsuhwd-7fxM_PK2TB1dkn9ZvZGTLB4lW-j7OnyRp-cLU3jyGzBYf6QtOguWA5UG99KlJok5GHAvpniBTxRN5vzF1qryaQPwEtqmX6Ayib-zGVuhFZxNIerI87J9wlhjLg0_jfkz5gRKRH9bgsNAlJ6uXqAWJOB0fO-PbSKFz=s0-d-e1-ft)
- FDA Collaborations Promote Rigorous Analyses of Real-World Data to Inform Pandemic Response
FDA has entered into an agreement with Aetion to collaborate on advanced analytical techniques to answer urgent COVID-19 research questions about the use of diagnostics and medications during the pandemic, and risk factors for COVID-19-related complications in different patient populations.
Learn more.
- Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is a public-private partnership led by the National Institutes of Health (NIH) and coordinated by the Foundation for the National Institutes of Health (FNIH) to develop a research strategy for prioritizing and speeding development of the most promising COVID-19 vaccines and treatments.
ACTIV brings together NIH with its sibling agencies in the Department of Health and Human Services, including the Biomedical Advanced Research and Development Authority (BARDA), Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA); other government agencies, including the Department of Defense (DOD) and Department of Veterans Affairs (VA); the European Medicines Agency (EMA); and representatives from academia, philanthropic organizations and biopharmaceutical companies.
Learn more.
No hay comentarios:
Publicar un comentario